Ligand director granted RSUs and stock options
LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026.
Rhea-AI Filing Summary
LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026. He was granted 836 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 31,560 shares.
He was also granted a Non-Qualified Stock Option for 2,938 shares of common stock at an exercise price of 237.0000 per share, expiring on June 5, 2036. Both the RSUs and the option award fully vest on the earlier of the next annual meeting of company stockholders following the grant date or the first anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 3,774 shares
Grant/Award
2 txns
Insider
LAMATTINA JOHN L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 2,938 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 836 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 2,938 contracts (Direct);
Common Stock — 31,560 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- F2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Key Figures
RSUs granted: 836 shares
Options granted: 2,938 options
Option exercise price: 237.0000 per share
+2 more
5 metrics
RSUs granted
836 shares
Restricted stock units granted June 5, 2026
Options granted
2,938 options
Non-Qualified Stock Option for common stock
Option exercise price
237.0000 per share
Strike price for 2,938-share option grant
Option expiration
June 5, 2036
Expiration date of granted Non-Qualified Stock Option
Shares held after RSU grant
31,560 shares
Direct common stock holdings after RSU award
Key Terms
restricted stock units ("RSUs"), Non-Qualified Stock Option, annual meeting, vests
4 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 237.0000 per share"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
annual meeting financial
"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
vests financial
"Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did LGND director John L. Lamattina receive?
John L. Lamattina received 836 restricted stock units and a Non-Qualified Stock Option for 2,938 shares of Ligand common stock. These awards were granted by the board as part of director compensation at the June 5, 2026 annual meeting.
What are the terms of John L. Lamattina’s new stock options in LGND?
He received a Non-Qualified Stock Option for 2,938 shares with an exercise price of 237.0000 per share, expiring on June 5, 2036. The options relate to Ligand common stock and vest based on the company’s director vesting schedule.
When do John L. Lamattina’s new LGND RSUs and options vest?
Both the 836 RSUs and the 2,938-share option grant fully vest on the earlier of the next annual meeting of Ligand stockholders following June 5, 2026, or the first anniversary of the June 5, 2026 grant date, aligning with the director compensation cycle.
Is John L. Lamattina’s Form 4 transaction a market purchase or sale of LGND stock?
The Form 4 reports compensation-related grants, not market trades. John L. Lamattina acquired RSUs and stock options from Ligand’s board at no cash price per share, rather than buying or selling shares in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
